Communiqués Illumina, Inc.

Actions

ILMN

US4523271090

Equipement et technologie médicale avancés

Temps réel estimé Cboe BZX 15:48:02 31/08/2026			Varia. 5j.	Varia. 1 janv.
210,10 ^USD	-2,55%		-4,00%	+63,38%

28/08	Illumina : un initié cède pour 85 241 664 $ d'actions, selon un récent document de la SEC	MT
24/08	Illumina : un initié cède pour 145 556 398 $ d'actions, selon un récent document de la SEC	MT

Communiqués

30/07	Illumina: Q2 Earnings Snapshot	AQ
30/07	Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026	PR
16/07	Illumina expands Billion Cell Atlas program with new AI drug developers	PR
09/07	Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026	PR
09/07	Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer	PR
23/06	Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors	PR
08/06	Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution	PR
28/05	Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research	PR
28/05	Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research	PR
21/05	David P. King elected to Illumina's Board of Directors	PR
19/05	Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact	PR
19/05	Illumina : CSR Report (illumina 2025 cr report fr)	PU
19/05	Illumina : CSR Report (illumina 2025 cr report en)	PU
04/05	Illumina : Quarterly Report for Quarter Ending March 29, 2026 (Form 10-Q)	PU
30/04	Illumina: Q1 Earnings Snapshot	AQ
30/04	Illumina Reports Financial Results for First Quarter of Fiscal Year 2026	PR
16/04	DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows	PR
14/04	Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease	PR
09/04	Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026	PR
02/04	Illumina Announces Changes to Board of Directors	PR
23/03	Illumina : CSR Report (2025 illumina france gender pay gap french)	PU
23/03	Illumina : CSR Report (2025 illumina france gender pay gap english)	PU
23/03	Illumina : CSR Report (2025 illumina gender pay gap uk)	PU
16/03	Illumina advances preventive genomics through strategic consortium with Veritas Genetics	PR
05/03	Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering	PR